Loading
A phase 3 trial of Intismeran autogene, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) is a phase 3 interventional study registered as NCT06077760 by Merck Sharp & Dohme LLC, with 868 participants planned, started 2023-12-06 and due to reach its primary completion in 2030-06-25. Interventions recorded: Intismeran autogene, Pembrolizumab, Placebo. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Resectable stage I to III non-small-cell lung cancer, Merck & Co. (MSD).
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD), Small-cell lung cancer.
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Resectable stage I to III non-small-cell lung cancer, Merck & Co. (MSD).
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD), Pembrolizumab.
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD), Pembrolizumab.
Shares Resectable stage I to III non-small-cell lung cancer, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD), Pembrolizumab.
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD).